2-chloro-6-isobutoxypyrazine | 1016508-48-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-chloro-6-isobutoxypyrazine
• 英文别名: 2-Chloro-6-(2-methylpropoxy)pyrazine
• CAS: 1016508-48-7
• 化学式: C₈H₁₁ClN₂O
• mdl: MFCD09807594
• 分子量: 186.641
• InChiKey: SDCKYWPFPKFGLU-UHFFFAOYSA-N

物化性质

• 沸点：
  234.3±35.0 °C(Predicted)
• 密度：
  1.154±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  35
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-chloro-6-isobutoxypyrazine 、 methyl (1S,2S)-2-(((6-(4-amino-3-methylisoxazol-5-yl)pyridin-3-yl)oxy)methyl)cyclohexane-1-carboxylate 在 tris-(dibenzylideneacetone)dipalladium(0) 、 sodium t-butanolate 、 2-二环己膦基-2'-(N,N-二甲胺)-联苯 作用下， 以 甲苯 为溶剂， 生成
  参考文献：
  名称：

  [EN] CYCLOHEXANE ACID DERIVATIVES AS LPA RECEPTOR INHIBITORS
  [FR] DÉRIVÉS D'ACIDE CYCLOHEXANE UTILISÉS EN TANT QU'INHIBITEURS DU RÉCEPTEUR DE LPA

  摘要：

  The present invention relates to a compounds of general formula (I) inhibiting lysophosphatidic acid receptor 1 (LPA1), particularly the invention relates to compounds that are cyclohexane acid derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of LPA receptors, in particular fibrosis.

  公开号：

  WO2023118253A1
• 作为产物：
  描述：

  异丁醇 、 2,6-二氯吡嗪 在 sodium hydride 作用下， 以 四氢呋喃 、 mineral oil 为溶剂， 反应 16.5h， 以83%的产率得到2-chloro-6-isobutoxypyrazine
  参考文献：
  名称：

  EP3239143

  摘要：

  公开号：

文献信息

• PIM KINASE INHIBITORS AND METHODS OF THEIR USE
  申请人：Burger Matthew

  公开号：US20120208815A1

  公开（公告）日：2012-08-16

  New compounds, compositions and methods of inhibition of kinase activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one serine/threonine kinase or receptor tyrosine kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.

  提供了一种用于抑制人或动物主体中与肿瘤发生相关的激酶活性的新化合物、组合物和方法。在某些实施例中，这些化合物和组合物能够有效地抑制至少一种丝氨酸/苏氨酸激酶或受体酪氨酸激酶的活性。这些新的化合物和组合物可以单独使用或与至少一种额外的药物联合使用，用于治疗丝氨酸/苏氨酸激酶或受体酪氨酸激酶介导的疾病，如癌症。
• PIM kinase inhibitors and methods of their use
  申请人：Burger Matthew

  公开号：US08822497B2

  公开（公告）日：2014-09-02

  New compounds, compositions and methods of inhibition of kinase activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one serine/threonine kinase or receptor tyrosine kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.

  本发明提供了一种用于抑制与人或动物主体中肿瘤发生相关的激酶活性的新化合物、组合物和方法。在某些实施例中，这些化合物和组合物能够有效抑制至少一种丝氨酸/苏氨酸激酶或受体酪氨酸激酶的活性。这些新的化合物和组合物可以单独使用或与至少一种其他药物联合使用，用于治疗丝氨酸/苏氨酸激酶或受体酪氨酸激酶介导的疾病，例如癌症。
• BIARYL DERIVATIVE AS GPR120 AGONIST
  申请人：LG Chem, Ltd.

  公开号：EP3239143A2

  公开（公告）日：2017-11-01

  The present invention relates to a biaryl derivative expressed by the chemical formula 1, a method for producing the biaryl derivative, a pharmaceutical composition comprising same, and use of same, the biaryl derivative expressed by the chemical formula 1, as a GPR120 agonist, promoting GLP-1 generation in the gastro-intestinal tract, reducing insulin resistance in the liver, muscles and the like from anti-inflammatory activity in the macrophage, pancreatic cells and the like, and allowing effective use in prevention or treatment of inflammation or metabolic diseases such as diabetes, complications from diabetes, obesity, non-alcoholic fatty liver disease, fatty liver disease, and osteoporosis.

  本发明涉及一种由化学式1表示的生物芳基衍生物、生产该生物芳基衍生物的方法、包含该生物芳基衍生物的药物组合物以及该生物芳基衍生物的用途，由化学式1表示的生物芳基衍生物作为GPR120激动剂，促进胃肠道中GLP-1的生成、从巨噬细胞、胰腺细胞等的抗炎活性中降低肝脏、肌肉等的胰岛素抵抗，并可有效用于预防或治疗炎症或代谢性疾病，如糖尿病、糖尿病并发症、肥胖症、非酒精性脂肪肝、脂肪肝和骨质疏松症。
• Biaryl derivative as GPR120 agonist
  申请人：LG CHEM, LTD.

  公开号：US11261186B2

  公开（公告）日：2022-03-01

  Compounds having the chemical formula 1, a method for producing the compounds of chemical formula 1, a pharmaceutical composition comprising same, and use thereof as a GPR120 agonist for prevention or treatment of inflammation or metabolic diseases such as diabetes, complications from diabetes, obesity, non-alcoholic fatty liver disease, fatty liver disease, and osteoporosis.

  具有化学式1的化合物，制备所述化学式1化合物的方法，包含所述化合物的药物组合物，以及将其用作一种GPR120激动剂，用于预防或治疗炎症或代谢性疾病，如糖尿病、糖尿病并发症、肥胖症、非酒精性脂肪肝病、脂肪肝病和骨质疏松症。
• US8822497B2
  申请人：——

  公开号：US8822497B2

  公开（公告）日：2014-09-02